Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $3.31, for a total value of $331,000.00. Following the transaction, the chief executive officer now directly owns 2,411,055 shares in the company, valued at $7,980,592.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Jong Joseph Kim also recently made the following trade(s):
- On Thursday, May 16th, Jong Joseph Kim sold 136,768 shares of Inovio Pharmaceuticals stock. The stock was sold at an average price of $3.50, for a total value of $478,688.00.
INO traded down $0.10 during trading on Thursday, reaching $3.25. 760,112 shares of the company were exchanged, compared to its average volume of 1,184,908. The company has a market cap of $338.22 million, a P/E ratio of -3.10 and a beta of 1.70. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92. Inovio Pharmaceuticals Inc has a 52 week low of $3.02 and a 52 week high of $6.30.
Several large investors have recently added to or reduced their stakes in the company. M Holdings Securities Inc. bought a new position in shares of Inovio Pharmaceuticals in the first quarter worth $54,000. BlueMountain Capital Management LLC grew its stake in shares of Inovio Pharmaceuticals by 199.7% in the first quarter. BlueMountain Capital Management LLC now owns 42,750 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 28,488 shares in the last quarter. Jefferies Group LLC bought a new position in shares of Inovio Pharmaceuticals in the first quarter worth $106,000. Geode Capital Management LLC grew its stake in shares of Inovio Pharmaceuticals by 12.7% in the first quarter. Geode Capital Management LLC now owns 1,131,213 shares of the biopharmaceutical company’s stock worth $4,219,000 after purchasing an additional 127,118 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Inovio Pharmaceuticals by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 502,380 shares of the biopharmaceutical company’s stock worth $1,874,000 after purchasing an additional 11,008 shares in the last quarter. 46.01% of the stock is owned by institutional investors.
Several equities research analysts recently issued reports on the company. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd. HC Wainwright restated a “buy” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, May 7th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Thursday, February 14th. Finally, Cantor Fitzgerald assumed coverage on Inovio Pharmaceuticals in a research note on Monday, March 25th. They set an “overweight” rating and a $3.62 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $7.57.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/05/23/inovio-pharmaceuticals-inc-ino-ceo-jong-joseph-kim-sells-100000-shares.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Further Reading: Trading Options- What is a Strangle?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.